Biosimilar switching is due to costs, formulary, relocation. Study of 23 studies, 3657 pts found only observational data
Tweet Content
Biosimilar switching is due to costs, formulary, relocation. Study of 23 studies, 3657 pts found only observational data, no RCTs. Ref product to biosimilar usually RCTs; Biosimilar switches usually real world evidence w/ good efficacy & no new risks. https://t.co/odAYHdbVd1 https://t.co/BabkVYsMBL
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off